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INTRODUCTION
Bronchoplastic procedures were initially designed for can-
cer patients unable to tolerate pneumonectomy, for those with
low grade malignancies, or for the treatment of benign lesions.
Despite substantial improvements in multimodality therapies,
operative resection remains the most important element in
curative therapy for lung cancer. Bronchoplastic lobectomy
was first performed in 1947 (1) and was first applied to a lung
cancer patient in 1952 to conserve lung parenchyma (2). This
procedure altered the approach to selected malignant neo-
plasms and has gradually gained acceptance as the standard
resection technique for lung cancer in elderly patients or pati-
ents with associated co-morbidity factors, in whom pneumo-
nectomy would be hazardous (3, 4). However, bronchoplastic
lobectomy was initially believed to carry a high risk due to
bronchial anastomoses that can give rise to specific compli-
cations, including dehiscence, vascular fistula, and stenosis.
Although bronchoplastic lobectomy has been applied to
lung cancer patients who could not tolerate pneumonecto-
my (3, 4), it has also been used in patients who could toler-
ate pneumonectomy (5, 6). Recent reports have suggested
that bronchoplastic lobectomy should be used routinely in
the management of patients with centrally located tumors,
even in those with sufficient pulmonary reserve, and could
achieve adequate cure rates (7, 8). To date, no randomized
trials comparing bronchoplastic lobectomy with pneumonec-
tomy have been performed, and they are unlikely to be per-
formed. Thus, all available information is derived from unma-
tched, retrospective cohorts of patients. In the present study,
to determine the feasibility and safety of bronchoplastic lobec-
tomy in the treatment of respectable non-small cell lung can-
cer (NSCLC), we retrospectively compared rates of operative
mortality and complications in patients treated with bron-
choplastic lobectomy and pneumonectomy.
MATERIALS AND METHODS
Patients
From March 1993 through December 2005, 1,461 consec-
utive patients clinically diagnosed with resectable NSCLC
underwent surgical resections in a single institution, including
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Comparison of Operative Mortality and Complications between 
Bronchoplastic Lobectomy and Pneumonectomy in Lung Cancer
Patients
Bronchoplastic lobectomy is a lung-saving procedure indicated for central tumors,
for which the alternative is pneumonectomy. We compared operative mortality and
complications between bronchoplastic lobectomy and pneumonectomy in lung can-
cer patients. From March 1993 through December 2005, 1,461 patients were surgi-
cally resected for non-small cell lung cancer, including 73 who underwent broncho-
plastic lobectomy and 258 who underwent pneumonectomy. Bronchoplastic lobec-
tomy was performed on any lesion that could be completely resected by this tech-
nique, whereas pneumonectomy was only performed on lesions that could not be
removed by bronchoplastic lobectomy. Operative deaths occurred in 1 of 73 (1.4%)
bronchoplastic lobectomy and 26 of 258 (10.1%) pneumonectomy patients (p=
0.014). Major complications occurred in 16 of 73 (21.9%) bronchoplastic lobecto-
my and 58 of 258 (22.5%) pneumonectomy patients (p=1.0). Bronchoplastic lobec-
tomy has a lower risk of operative mortality than pneumonectomy. Although the
complication rates were similar, bronchoplastic lobectomy was associated with im-
proved postoperative cardiopulmonary status and a low prevalence of fatal com-
plications after bronchial anastomosis. These findings indicate that bronchoplastic
lobectomy is a valuable alternative to pneumonectomy for anatomically appropri-
ate patients, regardless of underlying cardiopulmonary function.
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73 who underwent bronchoplastic lobectomy and 258 who
underwent pneumonectomy. Of the 73 bronchoplastic lobec-
tomy patients, full sleeve resection was performed on 56 and
bronchoplasty with bronchial wedge excision was performed
on 17. Patients underwent bronchoplastic lobectomy if their
lesions could be completely resected by this technique, includ-
ing patients with central tumors located at the origin of a lobar
bronchus, patients with positive bronchial resection margin
after standard lobectomy, and patients with N1 disease when
both tumor and nodes could be completely resected. Patients
underwent pneumonectomy only for lesions that could not
be removed by bronchoplastic lobectomy. No attempt was
made to match the groups, but they were fairly comparable
in age, sex, histology, site, FEV1, stage, and nodal status.
All patients were staged according to the 1997 revisions in
the international system for staging lung cancer. Operative
mortality included 30 day mortality, all in-hospital mortality
beyond 30 days, and mortality at home due to a cause strictly
related to the operation. Complications were scored as anas-
tomotic (bronchial) complications, specific surgical compli-
cations, and nonspecific surgical or medical complications.
Operative and post-operative management
All operations were carried out under general anesthesia
with a double lumen endotracheal tube and through a pos-
terolateral thoracotomy. A thoracic epidural infusion was used
for postoperative analgesia. Bronchial anastomosis was per-
formed using whole layer interrupted 4-0 absorbable polyfil-
ament sutures, and a telescopic method was routinely used
due to proximal and distal bronchial size discrepancy (lumi-
nal disparity). Inferior pulmonary ligament release maneuver
was routinely performed, but pericardial release and bronchial
anastomosis wrapping were not routine. Mediastinal lym-
phadenectomy was performed in all cases. Prior to closure of
the thoracotomy, the anastomosis was checked with inflation
pressures of 35-40 cm H2O. Intraoperative fiberoptic bron-
choscopy was routinely used to assess the anastomosis at the
end of operation.
Statistical analysis
Results are presented as mean±SD for continuous vari-
ables and as percentages for categorical variables. Qualitative
data was compared using the chi-square test and differences
between means were analyzed by Fisher’s exact t-test. A p-
value of 0.05 or less was considered statistically significant.
RESULTS
Age and sex
The bronchoplastic lobectomy group consisted of 67 men
and 6 women, of mean age 57.5±13.6 yr (range, 13 to 77
yr). The pneumonectomy group consisted of 227 men and
31 women, of mean age 61.1±9.8 yr (range, 19 to 81 yr).
Staging and histology
Histologic characteristics and postoperative pathologic stag-
ing for both groups are shown in Table 1. In the bronchoplas-
tic lobectomy group, the rates of carcinoid and stage 1B tu-
mors were high and the rate of adenocarcinoma was low com-
pared with the pneumonectomy group. 
Sites of lung resection
Bronchoplastic lobectomies were performed on 31 right
upper lobes (42.5%), 18 left lower lobes (24.7%), 16 left upper
lobes (21.9%), and 8 other lobes (10.9%), whereas pneumo-
nectomies were performed on 114 right lungs (44.2%) and
144 left lungs (55.8%) (Table 2).
Early outcomes
Postoperative mortality rates are shown in Table 3. There
Group I 
(n=73)
Group II 
(n=258)
p-
value
Age (yr) 57.5±13.6 61.1±9.8 <0.05
Men 67 (91.8%) 227 (88.0%) NS
Women 6 (8.2%) 31 (12.0%) NS
Smoking 61 (83.6%) 227 (88.0%) NS
Duration (Pack years) 43.8±22.4 41.2±17.7 NS
Histology
Squamous cell carcinoma 58 (79.5%) 187 (72.5%) NS
Adenocarcinoma 5 (6.8%) 47 (18.2%) <0.05
Adenosquamous 1 (1.4%) 5 (1.9%) NS
Carcinoid 3 (4.1%) 1 (0.4%) <0.05
Others 6 (8.2%) 18 (7.0%) NS
Stage IA 2 (2.7%) 5 (1.9%) NS
IB 34 (46.6%) 62 (24.0%) <0.001
IIA 4 (5.5%) 4 (1.6%) NS
IIB 13 (17.8%) 74 (28.7%) NS
IIIA 13 (17.8%) 75 (29.1%) NS
IIIB 6 (8.2%) 22 (8.5%) NS
Others 1 (1.4%) 16 (6.2%) NS
p T 1 6 (8.2%) 12 (4.8%) NS
2 51 (69.9%) 166 (66.7%) NS
3 10 (13.7%) 47 (18.9%) NS
4 6 (8.2%) 24 (9.6%) NS
p N 0 44 (60.3%) 91 (35.5%) <0.001
1 20 (27.4%) 92 (35.9%) NS
2 9 (12.3%) 73 (28.5%) <0.01
Neoadjuvant therapy 7 (9.6%) 26 (10.1%) NS
Chemotherapy only 5 (6.8%) 13 (5.1%) NS
Chemoradiotherapy 2 (2.7%) 13 (5.1%) NS
FEV1 (L) 2.35±0.46 2.35±0.55 NS
FEV1 (% of predicted) 83.1±15.6 86.8±17.0 NS
FEV1 <70% predicted (%) 9 (12.3%) 36 (14.0%) NS
Table 1. Patient characteristicswas a single operative mortality among the 73 patients who
underwent bronchoplastic lobectomies (1.4%). This patient,
a 68 yr old man with diabetes mellitus who underwent a coro-
nary artery bypass graft prior to bronchoplastic right lower
lobe lobectomy, died on postoperative day 58 of pneumonia
and acute respiratory distress syndrome (ARDS) due to a post-
operative bronchopleural fistula (BPF) of unknown cause that
developed proximal to the anastomosis site.
In contrast, operative mortality occurred in 26 of the 258
patients (10.1%) who underwent pneumonectomy, a rate sig-
nificantly higher than that observed in patients who under-
went bronchoplastic lobectomy (p=0.014). The major cause
of death in patients who underwent pneumonectomy was
pulmonary complications, including pneumonia (46.2%) and
ARDS (26.9%).
There were no significant difference in anastomotic (bron-
chial), specific surgical, and nonspecific surgical or medical
complications between patients who underwent bronchoplas-
tic lobectomy and those who underwent pneumonectomy
(Table 4).
DISCUSSION
Surgical approaches to lung cancer vary from limited paren-
chymal resection for peripheral, small, and early-stage cancers
to pneumonectomy for centrally located tumors with nodal
involvement. Preoperative cardiopulmonary function and the
amount of pulmonary parenchyma resected influence post-
operative functional performance and likely affect postoper-
ative quality of life (3, 7, 9). Therefore, individualization of
technique is important for survival and quality of life out-
comes.
Bronchoplastic lobectomy is a technically more demand-
ing procedure than standard lobectomy and pneumonecto-
my, and any resulting bronchial anastomosis can give rise to
specific complications. This is one reason that initial efforts
at parenchyma-sparing operations focused on patients with
limited pulmonary reserve who were not candidates for pneu-
monectomy (3, 4). Based on favorable experiences with such
patients, the indications for bronchoplastic lobectomy expand-
ed to include patients with anatomically favorable tumors
regardless of their preoperative pulmonary status (5-8). We
found that patients who underwent bronchoplastic lobecto-
my had lower rates of ARDS and pneumonia (1.4% and 6.8%,
respectively) than those who underwent pneumonectomy
(9.3% and 12.0%, respectively). Since preservation of lung
parenchyma is believed to reduce the risks of operative mor-
tality and should improve functional capacity and possible
quality of life in the long term, it is logical that the incidence
of respiratory failure was lower after bronchoplastic lobectomy.
Parenchymal sparing bronchoplastic lobectomy has several
advantages compared with pneumonectomy. Postoperative-
ly, mortality and morbidity should be lower (3, 10, 11), due
to the avoidance of deleterious and procedure-specific com-
plications of pneumonectomy, including pulmonary edema,
bronchopleural fistula, and pneumonia, a finding supported
by our results. The mortality rate following pneumonectomy
has been reported to range from 4.1% to 10% (3, 10, 12, 16),
whereas the mortality rate following bronchoplastic lobec-
tomy ranged from 1.3% to 7% (3, 6, 8, 10-17). We observed
mortality rates of 10.1% and 1.4%, respectively. Broncho-
plastic lobectomy was initially believed to be a higher risk
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Group I (n=73) Group II (n=258)
Right 39 (53.4%) 114 (44.2%)
RUL 31 (42.5%)
RLL 3 (4.1%)
RUL+RML 3 (4.1%)
RML+RLL 2 (2.7%)
Left 34 (46.6%) 144 (55.8%)
LUL 16 (21.9%)
LLL 18 (24.7%)
Table 2. Site of lung resection
RUL, right upper lobe; RLL, right lower lobe; RML, right middle lobe;
LUL, left upper lobe; LLL, left lower lobe.
Group I 
(n=73)
Group II 
(n=258)
p-value
Mortality
30-day mortality 0 (0.0%) 23 (8.9%) 0.004
Operative mortality 1 (1.4%) 26 (10.1%) 0.014
BPF 1 2 (7.7%)
Pneumonia 0 12 (46.2%)
ARDS 0 7 (26.9%)
Others 0 5 (19.2%)
Table 3. Mortality and cause of death
BPF, bronchopleural fistula; ARDS, acute respiratory distress syndrome.
Group I 
(n=73)
Group II 
(n=258)
p-
value
Bronchial (anastomotic) complications 5 (6.8%) 13 (5.0%) 0.562
BPF 3 (4.1%) 13 (5.0%)
BPF without empyema 2 (2.7%) 5 (1.9%)
BPF with empyema 1 (1.4%) 8 (3.1%)
Stenosis 2 (2.7%) 0
Specific surgical complications 10 (13.6%) 40 (15.5%) 0.853
Atelectasis 4 (5.5%) 2 (0.8%)
ARDS 1 (1.4%) 24 (9.3%)
Pulmonary hypertension 3 (1.2%) 0
Nonspecific surgical or medical  10 (13.7%) 43 (16.7%) 0.593
complications
Pneumonia 5 (6.8%) 31 (12.0%)
Arrhythmia 3 (4.1%) 8 (3.1%)
Others 2 (2.7%) 20 (7.8%)
Total 16 (21.9%) 58 (22.5%) 1.0
Table 4. Complication
BPF, bronchopleural fistula; ARDS, acute respiratory distress syndrome.46 E.-S. Lee, S.-I. Park, Y.H. Kim, et al.
procedure, due to a theoretical increase in the risk of anasto-
motic complications, including dehiscence, vascular fistula,
and stenosis (3, 4, 7, 9, 10, 14, 18). These complications,
however, are rare, due to improved surgical techniques that
preserve the bronchial blood supply, creation of a tension free
bronchial anastomosis, and improved suture materials, all of
which have resulted in better bronchial healing (4, 7, 12).
Therefore, bronchoplastic lobectomy appears to be an alter-
native to pneumonectomy regarding operative mortality and
morbidity (3, 7-10).
Regarding quality of life issues, lung-saving resections in-
cluding sleeve or bronchoplastic lobectomy preserve greater
respiratory capacity (19) than pneumonectomy and allow for
radical resection of secondary lung malignancies (12, 14),
which has increased in recent years. Mediastinal shifting and
right ventricular dysfunction, the deleterious cardiovascular
and hemodynamic consequences of pneumonectomy, result-
ed from increased pulmonary vascular resistance. These con-
sequences led to decreased diffusion capacity and elevated
pressures in the right side of the heart during exercise in most
patients, progression of emphysema and development of pul-
monary hypertension, resulting in cor pulmonale in some
patients (11, 20).
Specific procedure-related complications of bronchoplasty
were related with impaired anastomotic healing and reten-
tion of bronchial secretions. Anastomotic disruption and sub-
sequent fistularization to the pulmonary artery have not been
reported recently. The incidence of anastomotic dehiscence
and BPF has been reported to range from 0% to 6% (3, 7, 9,
10, 12, 14), in agreement with our finding of 4.1%. Anasto-
motic strictures respond to a dual mechanism; that is, bron-
chial ischemia occurs following sleeve bronchoplasty, where-
as, in cases of bronchial wedge excision, a too generous car-
tilaginous bridge may bulge into the lumen, causing an ob-
struction. The overall incidence of stenosis has been report-
ed to range from 3% to 9% (7, 16), in agreement with our
finding of 2.7%. The consequences of these complications
on patient outcomes, however, are considerably less deleteri-
ous than the complications of pneumonectomy (3, 6, 8, 10,
11, 21).
For anatomic reasons, right upper lobectomy is most suit-
able for bronchoplasty. Of our 73 patients who underwent
bronchoplastic lobectomy, 31 (42.5%) underwent right upper
lobectomy, a rate similar to that reported by others (3, 12-15).
The proximal transsection of the main stem bronchus is per-
formed at the same level as for pneumonectomy. On the left
side, the close anatomic location of the lobar take-offs narrows
the resection margin, an additional drawback to conservative
resection arises when the uppermost branches of the left pul-
monary artery are involved by the tumor.
No prospective studies comparing bronchoplastic lobec-
tomy and pneumonectomy have been conducted. Retrospec-
tive studies, however, have shown comparable mortality and
survival rates for the two procedures. In our series, the oper-
ative mortality rate was 1.4% in the group of patients who
underwent bronchoplastic lobectomies, compared with 10.1%
for the group of patients who underwent pneumonectomies,
whereas major complication rates were similar in the two
groups (21.9% vs. 22.5%). Although the comparison of these
two groups was retrospective and nonrandomized, these results
suggest that bronchoplastic lobectomy is superior to pneu-
monectomy in selected patients. This may be due to the im-
proved postoperative cardiopulmonary status after broncho-
plastic lobectomy, owing to the preservation of lung parenchy-
ma. Moreover, bronchial anastomosis can be performed with
a low rate of complications.
In conclusion, our results indicate that bronchoplastic lo-
bectomy is a valuable alternative to pneumonectomy for ana-
tomically appropriate patients, regardless of their underlying
cardiopulmonary function, owing to a substantially lower
operative mortality rate.
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